Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE- 206)

NCT02665650 is registered in ClinicalTrials.gov with Affimed GmbH as lead sponsor.

NCT NCT02665650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02665650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE- 206)
Lead sponsor
Affimed GmbH
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2016
Completion date
March 31, 2019
Enrollment
30 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma